SICS: effective solution to huge cataract problem

Article

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world.

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world, said Dr Satyajit Sinha of the AB Eye Institute, Patma, India.

"India's population has just topped 1 billion. There are 16 million cataract patients, and two million are added every year," said Dr Sinha. "But there are just 16,000 ophthalmologists, with 10,000 operating, which means there is a huge patient load for each doctor. We need a simple and effective way to combat cataract."

In this context, the choice of surgery must be weighed against the pressing need for treatment. Extra capsular cataract extraction (ECCE) has a short learning curve, SICS a longer one, but phaco requires a difficult and lengthy apprenticeship. Complications caused by 'in-training calamities' are worse with phaco, Dr Sinha noted.

SICS has a number of advantages. It means earlier rehab for patients than ECCE. There are no complications with sutures or suture removal. It has advantages over phaco for grade three, four and five cataracts. Patients are happy, too.

"One side of the globe is phaco. But on the other side of the globe, where cost is a big factor, we use SICS," he said. "Now high-quality, low-cost surgical instruments are being made indigenously by Indian companies. You can buy a crescent and keratome for $2. You can perform a SICS surgery and buy the IOL for $20 per patient. Phaco machines, by contrast, are expensive," said Dr Sinha.

As a result, India has the most SICS surgeons in the world, and highest number of SICS training centres.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.